Neuro-Oncology
Palliative and end-of-life care for neuro-oncology patients
Jul. 21, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Axial T2 FLAIR sequence MRI (A) showing bithalamic hyperintensities (arrows), the FLAIR hyperintensities are also scattered throughout the supra- (arrowheads) and infratentorial areas (not demonstrated) in a patient with negative serum studies but isolated positive MOG IgG in the CSF. (B) T1 post-contrast sequence from the same patient with correlated T1 hypointensities (arrows) without associated enhancement. (Contributed by Dr. Lama Abdel Wahed.)